333 related articles for article (PubMed ID: 15455405)
1. mTOR cascade activation distinguishes tubers from focal cortical dysplasia.
Baybis M; Yu J; Lee A; Golden JA; Weiner H; McKhann G; Aronica E; Crino PB
Ann Neurol; 2004 Oct; 56(4):478-87. PubMed ID: 15455405
[TBL] [Abstract][Full Text] [Related]
2. Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis.
Miyata H; Chiang AC; Vinters HV
Ann Neurol; 2004 Oct; 56(4):510-9. PubMed ID: 15455398
[TBL] [Abstract][Full Text] [Related]
3. Doublecortin-like (DCL) expression in focal cortical dysplasia and cortical tubers.
Boer K; Lucassen PJ; Spliet WG; Vreugdenhil E; van Rijen PC; Troost D; Jansen FE; Aronica E
Epilepsia; 2009 Dec; 50(12):2629-37. PubMed ID: 19583781
[TBL] [Abstract][Full Text] [Related]
4. Cellular localization of metabotropic glutamate receptors in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex.
Boer K; Troost D; Timmermans W; Gorter JA; Spliet WG; Nellist M; Jansen F; Aronica E
Neuroscience; 2008 Sep; 156(1):203-15. PubMed ID: 18706978
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
6. Cytoarchitectural alterations are widespread in cerebral cortex in tuberous sclerosis complex.
Marcotte L; Aronica E; Baybis M; Crino PB
Acta Neuropathol; 2012 May; 123(5):685-93. PubMed ID: 22327361
[TBL] [Abstract][Full Text] [Related]
7. mTOR pathway activation in focal cortical dysplasia.
Kumari K; Sharma MC; Kakkar A; Malgulwar PB; Pathak P; Suri V; Sarkar C; Chandra SP; Faruq M
Ann Diagn Pathol; 2020 Jun; 46():151523. PubMed ID: 32325422
[TBL] [Abstract][Full Text] [Related]
8. Analysis of chromosomal instability in focal cortical dysplasia of Taylor's balloon cell type.
Fassunke J; Blümcke I; Lahl R; Elger CE; Schramm J; Merkelbach-Bruse S; Mathiak M; Wiestler OD; Becker AJ
Acta Neuropathol; 2004 Aug; 108(2):129-34. PubMed ID: 15235806
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of fibroblast growth factor (FGF)-2 in epilepsy-associated malformations of cortical development (MCDs).
Sugiura C; Miyata H; Ueda M; Ohama E; Vinters HV; Ohno K
Neuropathology; 2008 Aug; 28(4):372-81. PubMed ID: 18179408
[TBL] [Abstract][Full Text] [Related]
10. Biallelic TSC gene inactivation in tuberous sclerosis complex.
Crino PB; Aronica E; Baltuch G; Nathanson KL
Neurology; 2010 May; 74(21):1716-23. PubMed ID: 20498439
[TBL] [Abstract][Full Text] [Related]
11. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.
Ma L; Teruya-Feldstein J; Bonner P; Bernardi R; Franz DN; Witte D; Cordon-Cardo C; Pandolfi PP
Cancer Res; 2007 Aug; 67(15):7106-12. PubMed ID: 17671177
[TBL] [Abstract][Full Text] [Related]
12. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation.
Uhlmann EJ; Li W; Scheidenhelm DK; Gau CL; Tamanoi F; Gutmann DH
Glia; 2004 Aug; 47(2):180-8. PubMed ID: 15185396
[TBL] [Abstract][Full Text] [Related]
13. Focal cortical dysplasia of Taylor's balloon cell type: mutational analysis of the TSC1 gene indicates a pathogenic relationship to tuberous sclerosis.
Becker AJ; Urbach H; Scheffler B; Baden T; Normann S; Lahl R; Pannek HW; Tuxhorn I; Elger CE; Schramm J; Wiestler OD; Blümcke I
Ann Neurol; 2002 Jul; 52(1):29-37. PubMed ID: 12112044
[TBL] [Abstract][Full Text] [Related]
14. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
15. Cyst-like tubers are associated with TSC2 and epilepsy in tuberous sclerosis complex.
Chu-Shore CJ; Major P; Montenegro M; Thiele E
Neurology; 2009 Mar; 72(13):1165-9. PubMed ID: 19332694
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathogenesis of focal cortical dysplasia and hemimegalencephaly.
Crino PB
J Child Neurol; 2005 Apr; 20(4):330-6. PubMed ID: 15921235
[TBL] [Abstract][Full Text] [Related]
17. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
Kenerson HL; Aicher LD; True LD; Yeung RS
Cancer Res; 2002 Oct; 62(20):5645-50. PubMed ID: 12384518
[TBL] [Abstract][Full Text] [Related]
18. mTOR and P70 S6 kinase expression in primary liver neoplasms.
Sahin F; Kannangai R; Adegbola O; Wang J; Su G; Torbenson M
Clin Cancer Res; 2004 Dec; 10(24):8421-5. PubMed ID: 15623621
[TBL] [Abstract][Full Text] [Related]
19. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.
Conde E; Angulo B; Tang M; Morente M; Torres-Lanzas J; Lopez-Encuentra A; Lopez-Rios F; Sanchez-Cespedes M
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):710-7. PubMed ID: 16467080
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of cyclin D1 and phosphorylated ribosomal S6 proteins in hemimegalencephaly.
Aronica E; Boer K; Baybis M; Yu J; Crino P
Acta Neuropathol; 2007 Sep; 114(3):287-93. PubMed ID: 17483958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
